Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

Paterson, David L., Georghiou, Paul R., Allworth, Anthony M. and Kemp , Richard J. (1995) Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clinical Infectious Diseases, 20 2: 250-254.


Author Paterson, David L.
Georghiou, Paul R.
Allworth, Anthony M.
Kemp , Richard J.
Title Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection
Journal name Clinical Infectious Diseases   Check publisher's open access policy
ISSN 1058-4838
Publication date 1995-02
Sub-type Article (original research)
Volume 20
Issue 2
Start page 250
End page 254
Total pages 5
Place of publication Chicago, I.L., U.S.A.
Publisher University of Chicago Press
Language eng
Subject 1103 Clinical Sciences
1117 Public Health and Health Services
Abstract In recent years, thalidomide has been used for the treatment of a variety of ulcerative and immunologic conditions. Several previous reports have suggested that thalidomide therapy is beneficial for patients with aphthous ulceration related to human immunodeficiency virus (HIV) infection. We describe the use of thalidomide in 20 HIV-infected patients with oropharyngeal, esophageal, and rectal ulceration. Nineteen patients had a dramatic response to thalidomide therapy, with both subjective and objective abatement in the signs and symptoms of their ulcerative disease. The standard treatment course was 200 mg of thalidomide for 14 days (the drug was administered at night). Four patients required additional courses of treatment because symptoms recurred after thalidomide therapy was stopped. Side effects due to thalidomide included rash (5 patients), peripheral neuropathy (1 patient), and excessive fatigue (1 patient). There did not appear to be any adverse immunologic effects in thalidomide-treated patients. The mechanism of the effect of thalidomide is uncertain, although recent studies have suggested that thalidomide selectively inhibits the production of tumor necrosis factor α.
Keyword Hyperalgic Pharyngeal Ulceration
Systemic Lupus-erythematosus
Necrosis-factor-alpha
Esophageal Ulcers
Hiv-infection
Homosexual Men
AIDS
Recurrent
Association
Neuropathy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: UQ Centre for Clinical Research Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 74 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 86 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 07 Sep 2010, 17:07:22 EST